Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.82% | -4.26% | -1.45% | 6.98% | 0.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.82% | -4.26% | -1.45% | 6.98% | 0.09% |
| Cost of Revenue | 0.18% | -2.25% | 2.62% | 3.12% | -1.78% |
| Gross Profit | -8.90% | -12.17% | -18.21% | 24.75% | 7.35% |
| SG&A Expenses | 5.33% | 4.38% | 7.49% | 17.35% | 24.59% |
| Depreciation & Amortization | 3.62% | 4.22% | 1.26% | 0.11% | -2.23% |
| Other Operating Expenses | 53.87% | -155.56% | 51.59% | -61.99% | 62.76% |
| Total Operating Expenses | 0.91% | -1.66% | 3.50% | 3.98% | 0.59% |
| Operating Income | -21.97% | -28.16% | -74.77% | 39.88% | -3.43% |
| Income Before Tax | -49.23% | -49.88% | -155.32% | 14.53% | 9.48% |
| Income Tax Expenses | 1.65% | -73.47% | -114.38% | 98.58% | -19.97% |
| Earnings from Continuing Operations | -62.39% | -45.66% | -1,191.30% | -31.33% | 20.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 93.33% | 578.79% | 83.86% | -174.24% | -10.04% |
| Net Income | -61.77% | -44.00% | -412.34% | -33.16% | 21.23% |
| EBIT | -21.97% | -28.16% | -74.77% | 39.88% | -3.43% |
| EBITDA | -17.28% | -20.93% | -50.27% | 29.81% | -3.22% |
| EPS Basic | -61.44% | -43.27% | -418.18% | -31.61% | 22.97% |
| Normalized Basic EPS | -26.57% | -35.81% | -133.05% | 68.02% | -6.49% |
| EPS Diluted | -60.43% | -41.18% | -506.06% | -31.61% | 20.00% |
| Normalized Diluted EPS | -26.61% | -36.05% | -133.05% | 68.02% | -6.39% |
| Average Basic Shares Outstanding | -0.86% | -1.29% | -1.50% | -2.25% | -1.40% |
| Average Diluted Shares Outstanding | -0.78% | -1.03% | -1.50% | -2.25% | -1.55% |
| Dividend Per Share | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | 1.58% | 0.75% | 0.81% | 0.49% | -0.18% |